Randomized, open-label, single-dose, three-treatment, six-sequence, three-way crossover study to evaluate the safety and pharmacokinetic characteristics after coadministration of C1-R215 and C2-R215 compared to the administration of C1-R215 and C2-R215 independently in healthy male volunteers

Inclusion Criteria:

• Healthy male between 19 and 45
• BW is above 50kg and BMI is between 18.5 and 30.0
• Subject who agreed and signed on informed consent form prior to the study participation

Exclusion Criteria:

• Presence or history of clinically significant disease
• Treatment history of any drug which might affect IP within 10days
• History of other study drugs within 12weeks